The correlation between RAS and COVID-19, short review of the latest evidence

Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	F. Ferrara, A. Vitiello
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2019
Materias:	covid-19 ras sars-cov-2 pandemic Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/3352ce2cfc6445a79c63888cbafd3d85
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3352ce2cfc6445a79c63888cbafd3d85
record_format	dspace
spelling	oai:doaj.org-article:3352ce2cfc6445a79c63888cbafd3d852021-11-22T07:09:56ZThe correlation between RAS and COVID-19, short review of the latest evidence2220-76192313-739810.15789/2220-7619-TCB-1613https://doaj.org/article/3352ce2cfc6445a79c63888cbafd3d852019-06-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1613https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARS-CoV-2 in cells; evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARS-CoV-2 in cells; evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.F. FerraraA. VitielloSankt-Peterburg : NIIÈM imeni Pasteraarticlecovid-19rassars-cov-2pandemicInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 0, Iss 0 (2019)
institution	DOAJ
collection	DOAJ
language	RU
topic	covid-19 ras sars-cov-2 pandemic Infectious and parasitic diseases RC109-216
spellingShingle	covid-19 ras sars-cov-2 pandemic Infectious and parasitic diseases RC109-216 F. Ferrara A. Vitiello The correlation between RAS and COVID-19, short review of the latest evidence
description	Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARS-CoV-2 in cells; evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARS-CoV-2 in cells; evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.
format	article
author	F. Ferrara A. Vitiello
author_facet	F. Ferrara A. Vitiello
author_sort	F. Ferrara
title	The correlation between RAS and COVID-19, short review of the latest evidence
title_short	The correlation between RAS and COVID-19, short review of the latest evidence
title_full	The correlation between RAS and COVID-19, short review of the latest evidence
title_fullStr	The correlation between RAS and COVID-19, short review of the latest evidence
title_full_unstemmed	The correlation between RAS and COVID-19, short review of the latest evidence
title_sort	correlation between ras and covid-19, short review of the latest evidence
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2019
url	https://doaj.org/article/3352ce2cfc6445a79c63888cbafd3d85
work_keys_str_mv	AT fferrara thecorrelationbetweenrasandcovid19shortreviewofthelatestevidence AT avitiello thecorrelationbetweenrasandcovid19shortreviewofthelatestevidence AT fferrara correlationbetweenrasandcovid19shortreviewofthelatestevidence AT avitiello correlationbetweenrasandcovid19shortreviewofthelatestevidence
_version_	1718417848157601792

The correlation between RAS and COVID-19, short review of the latest evidence

Ejemplares similares